Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

61.15
+1.272.12%
Volume:872.35K
Turnover:52.82M
Market Cap:10.16B
PE:-17.57
High:61.77
Open:60.25
Low:59.78
Close:59.88
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.66
T/O Rate:0.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:23.11
PE(LYR):-25.68

Loading ...

Ionis Pharmaceuticals: Advancing Pipeline, HBV Phase III Success, and Robust Catalyst Flow Underpin Buy Rating

TIPRANKS
·
May 28

Ionis partner GSK reports B-Well 1, B-Well 2 trials meet primary endpoint

TIPRANKS
·
May 28

Ionis Partner GSK Announces Bepirovirsen Achieves Unprecedented Functional Cure Rates With Potential to Redefine Treatment for Chronic Hepatitis B

THOMSON REUTERS
·
May 28

A New, Powerful Cholesterol-Lowering Drug Is on the Horizon -- WSJ

Dow Jones
·
May 28

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

J.P. Morgan Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

TIPRANKS
·
May 20

Ionis Pharmaceuticals Initiated at Buy by Citigroup

Dow Jones
·
May 19

Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi

TIPRANKS
·
May 19

Assessing Ionis Pharmaceuticals (IONS) Valuation As Shares Cool After A Multi Year Run

Simply Wall St.
·
May 16

Ionis CEO Brett P. Monia disposes of USD 361,478 common shares

Reuters
·
May 16

Ionis Pharmaceuticals participates in a conference call with Cantor

TIPRANKS
·
May 15

BRIEF-Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study Of Diranersen

Reuters
·
May 14

Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study of Diranersen (Biib080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients With Early Alzheimer’s Disease

THOMSON REUTERS
·
May 14

Ionis director Joseph Loscalzo disposes of common shares worth $5.8 million

Reuters
·
May 07

Ionis director Joseph Klein III disposes of common shares worth $742,586.86

Reuters
·
May 06

Ionis Pharmaceuticals announces virtual annual shareholder meeting

Reuters
·
May 04

A Look At Ionis Pharmaceuticals (IONS) Valuation After FDA Priority Review Wins And Upgraded Revenue Guidance

Simply Wall St.
·
May 04

Ionis to present at Bank of America health care conference fireside chat

Reuters
·
May 01

Ionis EVP, Chief Business Officer Joseph Baroldi disposes of $116,755 common shares

Reuters
·
May 01

Ionis Pharmaceuticals price target raised to $100 from $95 at RBC Capital

TIPRANKS
·
Apr 30